Legend Biotech Corporation
LEGN
Ранг среди акций
#4432
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Цена акции
$19.04
Последняя синхронизация: 2026-10-20
Рыночная капитализация
$3.52B
Изменение (1 день)
2.09%
Изменение (1 год)
-42.06%
Страна
US
Торговля Legend Biotech Corporation (LEGN)
Категория
Healthcare
Коэффициент P/B для Legend Biotech Corporation (LEGN)
Коэффициент P/B на October 2026 TTM: 2.90
Согласно последним финансовым отчетам и цене акций Legend Biotech Corporation, текущий коэффициент P/B (TTM) составляет 2.90. В конце 2023 он составлял 4.23.
История P/B для Legend Biotech Corporation с 2017 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | 2.90 | 1.24% |
| 2024 | 2.86 | -32.46% |
| 2023 | 4.23 | -20.63% |
| 2022 | 5.33 | -23.44% |
| 2021 | 6.97 | 17.36% |
| 2020 | 5.94 | -129.87% |
| 2019 | -19.88 | -109.29% |
| 2018 | 213.90 | 6.56% |
| 2017 | 200.73 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | 115.89% |
US
|
|
| 13.2547 | 357.77% |
US
|
|
| 4.208 | 45.33% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 113.52% |
NL
|
